Suzhou Novoprotein Scientific Co. Ltd. A
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular … Read more
Suzhou Novoprotein Scientific Co. Ltd. A (688137) - Total Assets
Latest total assets as of June 2025: CN¥2.20 Billion CNY
Based on the latest financial reports, Suzhou Novoprotein Scientific Co. Ltd. A (688137) holds total assets worth CN¥2.20 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Suzhou Novoprotein Scientific Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how Suzhou Novoprotein Scientific Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Suzhou Novoprotein Scientific Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Suzhou Novoprotein Scientific Co. Ltd. A's total assets of CN¥2.20 Billion consist of 88.2% current assets and 11.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 29.2% |
| Accounts Receivable | CN¥59.96 Million | 2.7% |
| Inventory | CN¥76.08 Million | 3.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥18.21 Million | 0.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Suzhou Novoprotein Scientific Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suzhou Novoprotein Scientific Co. Ltd. A's current assets represent 88.2% of total assets in 2024, an increase from 78.7% in 2020.
- Cash Position: Cash and equivalents constituted 29.2% of total assets in 2024, down from 37.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 3.4% of total assets.
Suzhou Novoprotein Scientific Co. Ltd. A Competitors by Total Assets
Key competitors of Suzhou Novoprotein Scientific Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Suzhou Novoprotein Scientific Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Suzhou Novoprotein Scientific Co. Ltd. A generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Suzhou Novoprotein Scientific Co. Ltd. A is currently not profitable relative to its asset base.
Suzhou Novoprotein Scientific Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.93 | 23.75 | 31.42 |
| Quick Ratio | 25.04 | 22.83 | 30.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.85 Billion | CN¥ 1.96 Billion | CN¥ 2.08 Billion |
Suzhou Novoprotein Scientific Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Suzhou Novoprotein Scientific Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | CN¥2.22 Billion |
| Market Capitalization | $145.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Suzhou Novoprotein Scientific Co. Ltd. A's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Suzhou Novoprotein Scientific Co. Ltd. A's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Suzhou Novoprotein Scientific Co. Ltd. A (2020–2024)
The table below shows the annual total assets of Suzhou Novoprotein Scientific Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.22 Billion | -3.51% |
| 2023-12-31 | CN¥2.30 Billion | -1.48% |
| 2022-12-31 | CN¥2.33 Billion | +354.78% |
| 2021-12-31 | CN¥513.10 Million | +177.67% |
| 2020-12-31 | CN¥184.79 Million | -- |